We have located links that may give you full text access.
Cell-Free DNA Maps Tissue Injury and Correlates with Disease Severity in Lung Transplant Candidates.
American Journal of Respiratory and Critical Care Medicine 2023 December 21
RATIONALE: Plasma cell-free DNA levels correlate with disease severity in many conditions. Pre-transplant cell-free DNA may risk stratify lung transplant candidates for post-transplant complications.
OBJECTIVE: Evaluate if pre-transplant cell-free DNA levels and tissue sources identify patients at high risk of primary graft dysfunction and other pre- and post-transplant outcomes.
METHODS: This multicenter, prospective cohort study recruited 186 lung transplant candidates. Pre-transplant plasma samples were collected to measure cell-free DNA. Bisulfite sequencing was performed to identify the tissue sources of cell-free DNA. Multivariable regression models determined the association between cell-free DNA levels and the primary outcome of primary graft dysfunction and other transplant outcomes including Lung Allocation Score, chronic lung allograft dysfunction and death.
MEASUREMENTS AND MAIN RESULTS: Transplant candidates had 2-fold greater cell-free DNA levels than healthy controls (median [IQR]: 23.7 ng/mL [15.1-35.6] vs 12.9 ng/mL [9.9-18.4], p < 0.0001), primarily originating from inflammatory innate immune cells. Cell-free DNA levels and tissue sources differed by native lung disease category and correlated with the Lung Allocation Score (p<0.001). High pre-transplant cell-free DNA increased the risk of primary graft dysfunction (OR 1.60, 95% CI [1.09 - 2.46], p = 0.0220), and death (HR 1.43, 95% CI [1.07 - 1.92], p = 0.0171) but not chronic lung allograft dysfunction (HR 1.37, 95% CI [0.97 - 1.94], p = 0.0767).
CONCLUSIONS: Lung transplant candidates demonstrate a heightened degree of tissue injury with elevated cell-free DNA, primarily originating from innate immune cells. Pre-transplant plasma cell-free DNA levels predict post-transplant complications.
OBJECTIVE: Evaluate if pre-transplant cell-free DNA levels and tissue sources identify patients at high risk of primary graft dysfunction and other pre- and post-transplant outcomes.
METHODS: This multicenter, prospective cohort study recruited 186 lung transplant candidates. Pre-transplant plasma samples were collected to measure cell-free DNA. Bisulfite sequencing was performed to identify the tissue sources of cell-free DNA. Multivariable regression models determined the association between cell-free DNA levels and the primary outcome of primary graft dysfunction and other transplant outcomes including Lung Allocation Score, chronic lung allograft dysfunction and death.
MEASUREMENTS AND MAIN RESULTS: Transplant candidates had 2-fold greater cell-free DNA levels than healthy controls (median [IQR]: 23.7 ng/mL [15.1-35.6] vs 12.9 ng/mL [9.9-18.4], p < 0.0001), primarily originating from inflammatory innate immune cells. Cell-free DNA levels and tissue sources differed by native lung disease category and correlated with the Lung Allocation Score (p<0.001). High pre-transplant cell-free DNA increased the risk of primary graft dysfunction (OR 1.60, 95% CI [1.09 - 2.46], p = 0.0220), and death (HR 1.43, 95% CI [1.07 - 1.92], p = 0.0171) but not chronic lung allograft dysfunction (HR 1.37, 95% CI [0.97 - 1.94], p = 0.0767).
CONCLUSIONS: Lung transplant candidates demonstrate a heightened degree of tissue injury with elevated cell-free DNA, primarily originating from innate immune cells. Pre-transplant plasma cell-free DNA levels predict post-transplant complications.
Full text links
Related Resources
Trending Papers
Hemodynamic Support in Sepsis.Anesthesiology 2024 June 2
The New Challenge of Obesity - Obesity-Associated Nephropathy.Diabetes, Metabolic Syndrome and Obesity 2024
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app